Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Sort by: Date|Relevance

A psychedelic renaissance

Fifty-three years after LSD was banned by the FDA, psychedelic drugs are making a comeback. Only instead of being the pills, mushrooms and acid tabs that helped college students to “turn on, tune in, drop out” Timothy Leary-style, today’...
Richard (Rick) Mills | December 3, 2019 |

What happens To The Global Economy If Oil Collapses Below $40 – Part III

This, the final section of this multi-part research article, will continue our exploration of the consequences that may result from our ADL predictive modeling system's suggestion that Oil may continue to fall to levels below $40 over the next few months. In Part I an...
Chris Vermeulen | November 15, 2019 |

XPhyto: Proof of Concept for Mescalin Synthesis

It’s become a much talked-about story on both sides of the Atlantic. XPhyto Therapeutics Corp. ( CSE: XPHY ) (FSE: 4XT) (OTCQB: XPHYF) has earned considerable media coverage in recent months due to its expansion into the development of psychedelic d...
Marc Davis | June 9, 2021 |

The Coming Test of the Great S&P 500 Bull Run

S&P 500 has overcome Thursday’s intraday highs, breaking above the 50% Fibonacci retracement of the slide from the mid-Feb highs to the mid-March lows. The setup appears too bullish to ignore. Is it time to jump in on the long side, or is the air getting too th...
Monica Kingsley | April 15, 2020 |

Will Fed‘s Cap On Interest Rates Trigger Gold’s Rally?

Last week, the FOMC released the minutes from its last meeting. What implications do they carry for the gold market? FOMC Finally Acknowledges the Situation As Serious Last week, the FOMC has published minutes of its meeting from April 28-29. They show that the Fed...
Arkadiusz Sieron | May 27, 2020 |

Novamind Selected by Merck to Advance Research for Treatment-Resistant Depression

Novamind’s subsidiary, Cedar Clinical Research, to serve as a key clinical research site Independent validation of the expertise and capabilities of Novamind in managing clinical trials Adds to established track record conducting research a...
Featured Submission | March 18, 2021 |

Relmada Therapeutics Stock Soars on Phase 2 Depression Study Results

Shares of Relmada Therapeutics have traded wildly today after it announced Phase 2 results for its anti-depressant drug dextromethadone. The firm's shares have traded 100–200% higher today and the stock was halted several times trading due to extreme price volatility. ...
Streetwise Reports | October 16, 2019 |

The Repo Liquidity Crunch Reveals Market Stress. Will Gold Shine?

Last week, the Fed had to inject liquidity into the repo market for the first time since the Great Recession . Not once, but several times – and also commit to do more. Will such a crack in the proverbial dam let gold’s allure shine? Scramble for Liquidity ...
Arkadiusz Sieron | September 24, 2019 |

Could the coronavirus cause the next ‘Arab Spring’?

The rich are getting richer, inequality is on the rise, and the middle class, the backbone of the US economy since the 1950s, is shrinking. In 2018 the three highest-paid chief executives in the United States earned more than the output of several countries. Tesla&Close...
Richard (Rick) Mills | March 19, 2020 |

Axsome Therapeutics Shares Open 82% Higher on Phase 3 MDD Trial Outcome

Axsome Therapeutics shares reached a new 52-week high price today after the company reported that its AXS-05 drug achieved primary endpoint in the GEMINI Phase 3 trial in Major Depressive Disorder. The firm indicated that the positive results support a New Drug Application fil...
Streetwise Reports | December 17, 2019 |
1 2 3 4 5 6 7 8 9 10 ...